Panelists discuss how aflibercept 8 mg demonstrates improved durability and maintenance of visual gains compared with 2-mg dosing, potentially reducing treatment burden while maintaining a similar safety profile.
Video content above is prompted by the following:
Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.